Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 1091-1099

  Mishra, N ^a   Buelens, K ^a   Theyskens, S ^a   Compernolle, G ^a   Gils, A ^a   Declerck, P J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Fibrinolysis; Nanobody; ProCPU; Thrombin activatable fibrinolysis inhibitor; Zymogen

Indexed keywords

ASPARTIC ACID; ENZYME PRECURSOR; PLASMIN; THREONINE; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING KINETICS; BIOLOGICAL ACTIVITY; BIOTRANSFORMATION; BLOOD CLOT LYSIS; CATALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME SUBSTRATE; EPITOPE MAPPING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; SCREENING TEST; WILD TYPE;

ANTIBODIES, CATALYTIC; ASPARTIC ACID; CARBOXYPEPTIDASE U; CATALYSIS; ENZYME ACTIVATION; ENZYME STABILITY; EPITOPE MAPPING; EPITOPES; FIBRIN; FIBRINOLYSIS; HUMANS; HYDROLYSIS; KINETICS; LYSINE; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; THREONINE;

EID: 84861683835     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04738.x     Document Type: Article

References (23)

1. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
2. Mosnier LO, von dem Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
3. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
4. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
5. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase-U, a plasma carboxypeptidase with high-affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
6. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
7. Marx PF, Brondijk THC, Plug T, Romijn RA, Hemrika W, Meijers JCM, Huizinga EG. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 2008; 112: 2803-9.
8. Ceresa E, Peeters M, Declerck PJ, Gils A. Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential. J Thromb Haemost 2007; 5: 418-20.
9. Marx PF, Plug T, Havik SR, Morgelin M, Meijers JCM. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? J Thromb Haemost 2009; 7: 445-52.
10. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-23.
11. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004; 279: 27896-904.
12. Willemse JL, Polla M, Hendriks DF. The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays. Anal Biochem 2006; 356: 157-9.
13. Valnickova Z, Thogersen IB, Potempa J, Enghild JJ. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J Biol Chem 2007; 282: 3066-76.
14. Willemse JL, Heylen E, Hendriks DF. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate: a rebuttal. J Thromb Haemost 2007; 5: 1334-6.
15. Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008; 283: 8863-7.
16. Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8: 1302-12.
17. Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ. Modulation of TAFI function through different pathways - implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 3: 2745-53.
18. Buelens K, Hillmayer K, Compernolle G, Declerck PJ, Gils A. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ Res 2008; 102: 295-301.
19. Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, Gils A. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost 2011; 106: 90-101.
20. Ceresa E, Brouwers E, Peeters M, Jern C, Declerck P, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26: 423-8.
21. Valnickova Z, Thogersen IB, Potempa J, Enghild JJ. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolytic rate: reply to a rebuttal. J Thromb Haemost 2007; 5: 1336-7.
22. Muto Y, Suzuki K, Sato E, Ishii H. Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 2003; 461: 181-9.
23. Valnickova Z, Sanglas L, Arolas JL, Petersen SV, Schar C, Otzen D, Aviles FX, Gomis-Rüth FX, Enghild JJ. Flexibility of the thrombin-activatable fibrinolysis inhibitor pro- domain enables productive binding of protein substrates. J Biol Chem. 2010; 285: 38243-50.